Brain immune responses cognitive decline and dementia: Relationship with phenotype expression and genetic background

Mechanisms of Ageing and Development

Volumn 124, Issue 4, 2003, Pages 539-548

  Licastro, Federico ^a   Chiappelli, Martina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alzheimer's disease; Cytokine allele polymorphism; Inflammation

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 6;

ALLELE; ALZHEIMER DISEASE; ASTROCYTOSIS; CELL ACTIVATION; CLINICAL FEATURE; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; ENCEPHALITIS; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; MICROGLIA; NONHUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SENILE PLAQUE;

EID: 0037396305     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(03)00034-4     Document Type: Conference Paper

References (112)

1. Abraham C.R., Selkoe D.J., Potter H. Immunochemical identification of the serine protease inhibitor, alpha-1-antichymotrypsin in the brain amyloid deposits. Cell. 52:1988;487-501.
2. Abraham C.R., Shirahama T., Potter H. Alpha-1-antichymotrypsin is associated solely with amyloid and cell localization of alpha-1-antichymotrypsin. Neurobiol. Aging. 1:1990;123-129.
3. Altstiel L.D., Sperber K. Cytokines in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry. 15:1991;481-495.
4. Altstiel L.D., Lawlor B., Mohs R., Schmeidler J., Dalton A., Mehta P., Davis K. Elevated alpha-1-antichymotrypsin serum levels in a subset of non-demented first-degree relatives of Alzheimer's disease patients. Dementia. 6:1995;17-20.
5. Alvarez X.A., Franco A., Fernandez-Novoa F., Cacabelos R. Blood levels of histamine, IL-1 beta and TNF-alpha in patients with mild to moderate Alzheimer's disease. Mol. Chem. Neuropathol. 29:1996;237-252.
6. Angelis P., Sharf S., Mander A., Vajda F., Christophidis N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci. Lett. 244:1998;106-108.
7. Bagli M., Papassotiropoulos A., Jessen F., Schmitz S., Rao M.L., Maier W., Heun R. Identical distribution of the alpha 2-macroglobulin pentanucleotide deletion in subjects with Alzheimer disease and controls in a German population. Am. J. Med. Genet. 96:2000;775-777.
8. Banati R.B., Gehrmann J., Czech C., Monning U., Jones L.L., Konig G., Beyreuther K., Kreutzberg G.W. Early and rapid de novo synthesis of Alzheimer beta A4-amyloid precursor protein (APP) in activated microglia. Glia. 9:1993;199-210.
9. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and α-2-macroglobulin indicate an acute phase state in Alzheimer's disease cortex. FEBS Lett. 285:1991;111-114.
10. Bauer J., Ganter U., Strauss S., Stadtmuller G., Frommberger U., Bauer H., Volk B., Berger M. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 143:1992;650-657.
11. Baumann H., Gauldie J. The acute phase response. Immunol. Today. 15:1994;74-80.
12. Beach T.G., Walker R., McGeer E.G. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia. 2:1989;420-436.
13. Blacker D., Wilcox M.A., Laird N.M., Rodes L., Horvath S.M., Go R.C., Perry R., Watson B. Jr., Bassett S.S., McInnis M.G., Albert M.S., Hyman B.T., Tanzi R.E. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 19:1998;357-360.
14. Blennow K., Ricksten A., Prince J.A., Brookes A.J., Emahazion T., Wasslavik C., Bogdanovic N., Andreasen N., Batsman S., Marcusson J., Nagga K., Wallin A., Regland B., Olofsson H., Hesse C., Davidsson P., Minthon L., Jansson A., Palmqvist L., Rymo L. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J. Neural. Transm. 107:2000;1065-1079.
15. Bonaccorso S., Lin A., Song C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Vandewoude M., Dossche A., Maes M. Serotonine-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milane). 10:1998;316-323.
16. Breitner J.C., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J., Anthony J.C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 44:1994;227-232.
17. Bullido M.J., Guallar-Castillon P., Artiga M.J., Ramos M.C., Sastre I., Aldudo J., Frank A., Coria F., Rodriguez-Artalejo F., Valdivieso F. Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender. Neurosci. Lett. 289:2000;213-216.
18. Canning D.R., McKeon R.J., DeWitt D.A., Perry G., Wujek J.R., Frederickson R.C., Silver J. beta-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp. Neurol. 124:1993;289-298.
19. Chen L., Baum L., Ng H.K., Chan L.Y., Sastre I., Artiga M.J., Valdivieso F., Bullido M.J., Chiu H.F., Pang C.P. Apolipoprotein E promoter and alpha2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease. Neurosci. Lett. 269:1999;173-177.
20. Collins J.S., Perry R.T., Watson B. Jr., Harrell L.E., Acton R.T., Blacker D., Albert M.S., Tanzi R.E., Bassett S.S., McInnis M.G., Campbell R.D., Go R.C. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am. J. Med. Genet. 96:2000;823-830.
21. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
22. Crawford F., Town T., Freeman M., Schinka J., Gold M., Duara R., Mullan M. The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neurosci. Lett. 270:1999;133-136.
23. Dickson D.W., Farlo J., Davies P., Crystal H., Fuld P., Yen S.H. Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am. J. Pathol. 132:1988;86-101.
24. Dinarello C.A. Interleukin-1, Interleukin-1 receptor and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16:1998;457-499.
25. Durany N., Ravid R., Riederer P., Cruz-Sanchez F.F. Increased frequency of the alpha-1-antichymotrypsin T allele in cerebral amyloid angiopathy. Neuropathology. 20:2000;184-189.
26. Eikelenboom P., Vink-Starreveld M.L., Jansen W., Pronk J.C. C3 and haptoglobin polymorphism in dementia of the Alzheimer type. Acta Psychiatr. Scand. 69:1984;140-142.
27. Emmerling M.R., Watson M.D., Raby C.A., Spiegel K. The role of complement in Alzheimer's disease pathology. Biochim. Biophys. Acta. 1502:2000;158-171.
28. Eriksson S., Janciauskiene S., Lannfelt L. Alpha-1-antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc Natl. Acad. Sci. USA. 92:1995;2313-2317.
29. Ershler W.B. Interleukin-6: a cytokine production in mononuclear cells of healthy elderly people. Eur. J. Immunol. 23:1993;2375-2378.
30. Fagiolo U., Cossarizza A., Scala E., Fanales-Belasio E., Ortolani C., Cozzi E., Monti D., Franceschi C., Paganelli R. Increased cytokine production in mononuclear cells of elderly people. Eur. J. Immunol. 23:1993;2375-2378.
31. Fraser P.E., Nguyen J.T., McLachlan D.R., Abraham C.R., Kirschner D.A. Alpha-1-antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 6:1993;298-305.
32. Furby A., Leys D., Delacourte A., Buee L., Soetaert G., Petit H. Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease? J. Neurol. Neurosurg. Psychiatry. 54:1991;469.
33. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Terry G., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao Jun. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
34. Gauldie J., Richards C., Baumann H. IL-6 and the acute phase reaction. Res. Immunol. 143:1992;755-759.
35. Goldgaber D., Harris H.W., Hla T., Maciag T., Donelly R.J., Jacobsen J.S., Vitek M.P., Gajdusek Dc. Interleukin-1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA. 86:1989;7606.
36. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L. 3rd, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 86:1989;7611-7615.
37. Griffin W.S., Sheng J.G., Royson M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8:1998;65-72.
38. Grimaldi L.M.E., Casadei V.M., Ferri C., Veglia F., Licastro F., Annoni G., Biunno I., De Bellis G., Sorbi S., Mariani C., Canal N., Griffin W.S., Franceschi M. Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorfism. Ann. Neurol. 47:2000;361-365.
39. Haines J.L., Prochard M.L., Saunders A.M., Schildkraut J.M., Growdon J.H., Gaskell P.C., Farrer L.A., Auerbach S.A., Gusella J.F., Locke P.A., Rosi B.L., Yamaoka L., Small G.W., Conneally P.M., Roses A.D., Pericak-Vance M.A. No genetic effect of alpha-1-antichymotrypsin in Alzheimers disease. Genomics. 33:1996;53-56.
40. Hansen L.A., Armstrong D.M., Terry R.D. An immunohistochemical quantification of fibrous astrocytes in the aging human cerebral cortex. Neurobiol. Aging. 8:1987;1-6.
41. Head E., Azizeh B.Y., Lott I.T., Tenner A.J., Cotman C.W., Cribbs D.H. Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiol. Dis. 8:2001;252-265.
42. Higuchi S., Matsushita S., Nakane J., Arai H., Matsui T., Urakami K., Yuzuriha T., Takeda A. Alpha2-macroglobulin gene polymorphisms show racial diversity and are not associated with Alzheimer's disease. Neuroreport. 11:2000;1167-1171.
43. Hoke A., Canning D.R., Malemud C.J., Silver J. Regional differences in reactive gliosis induced by substrate-bound beta-amyloid. Exp. Neurol. 130:1994;56-66.
44. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
45. Hu C.J., Sung S.M., Liu H.C., Lee K.Y., Hsu W.C., Wong W.K., Lee C.C., Tsai C.H., Chang J.G. No association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese. Neurology. 53:1999;642-643.
46. Huell M., Strauss S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brain of Alzheimer's disease patients. Acta Neuropathol. 89:1995;544-551.
47. Janus C., Pearson J., Mclaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St. George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
48. Jhoo J.H., Kim K.W., Lee D.Y., Lee K.U., Lee J.H., Kim S.Y., Youn J.Y., Youn J.C., Woo J.I. Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans. J. Neurol. Sci. 184:2001;21-25.
49. Kalman J., Juhasz A., Laird G., Dickens P., Jardanhazy T., Rimanoczy A., Boncz I., Parry-Jones W.L., Janka Z. Serum interleukin-6 levels correlate with the severity of the dementia in Down's syndrome and Alzheimer's disease. Acta Neurol. Scand. 96:1997;236-240.
50. Kamboh M.I., Sanghera D.K., Ferrell R.E., DeKosky S.T. APOE 4 associated Alzheimer's disease risk is modified by alpha-1-antichymotrypsin polymorphism. Nat. Genet. 10:1995;486-488.
51. Kelso A. Cytokines: principles and prospect. Immunol. Cell Biol. 76:1998;300-317.
52. Khachaturian Z.S. The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease. Neurobiol. Aging. 23:2002;509-511.
53. Kordula T., Rydel R.E., Brigham E.F., Horn F., Heinrich P.C., Travis J. Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha-1-antichymotrypsin expression in human cortical astrocytes. J. Biol. Chem. 237:1998;4112-4118.
54. Kordula T., Bugno M., Rydel R.E., Travis J. Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes. J. Neurosci. 20:2000;7510-7516.
55. Korovaitseva G.I., Premkumar S., Grigorenko A., Molyaka Y., Galimbet V., Selezneva N., Gavrilova S.I., Farrer L.A., Rogaev E.I. Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease. Neurosci. Lett. 271:1999;129-131.
56. Koster M.N., Dermaut B., Cruts M., Houwing-Duistermaat J.J., Roks G., Tol J., Ott A., Hofman A., Munteanu G., Breteler M.M., van Duijn C.M., Van Broeckhoven C. The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology. 55:2000;678-684.
57. Liao A., Nitsch R.M., Greenberg S.M., Finckh U., Blacker D., Albert M., Rebeck G.W., Gomez-Isla T., Clatworthy A., Binetti G., Hock C., Mueller-Thomsen T., Mann U., Zuchowski K., Beisiegel U., Staehelin H., Growdon J.H., Tanzi R.E., Hyman B.T. Genetic association of an alpha-2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum. Mol. Genet. 7:1998;1953-1956.
58. Licastro F., Morini M.C., Polazzi E., Davis L.J. Increased serum alpha-1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. J. Neuroimmunol. 57:1995;71-75.
59. Licastro F., Parnetti L., Morini M.C., Davis L.J., Cucinotta D., Gaiti A., Senin U. Acute phase reactant alpha-1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 9:1995;112-118.
60. Licastro F., Mallory M., Hansen L.A., Malsiah E. Increased levels of a-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J. Neuroimmunol. 88:1998;105-110.
61. Licastro F., Pedrini S., Govoni M., Pession A., Ferri C., Annoni G., Casadei V., Veglia F., Bertolini S., Grimaldi L.M.E. Apolipoprotein E and alpha-1-antichymotrypsin allele polymorphism in sporadic and familiar Alzheimer's disease. Neurosci. Lett. 270:1999;129-132.
62. Licastro F., Campbell I.L., Kincaid C., Veinbergs I., Van Uden E., Rockenstein E., Mallory M., Gilbert J.R., Masliah E. A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease. Am. J. Pathol. 155:1999;869-875.
63. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., Grimaldi L.M.E. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signal from the brain? J. Neuroimmunol. 103:2000;97-102.
64. Licastro F., Pedrini S., Ferri C., Casadei V., Govoni M., Pession A., Sciacca F.L., Veglia F., Annoni G., Bonafe M., Olivieri F., Franceschi C., Grimaldi L.M.E. Gene polymorphism affecting alpha-1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann. Neurol. 48:2000;388-391.
65. Licastro F., Pedrini S., Davis L.J., Caputo L., Tagliabue J., Savorani G., Cucinotta D., Annoni G. Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. Alzheimer Dis. Assoc. Dis. 15:2001;51-55.
66. Licastro, F., Grimaldi, L.M.E., Bonafè, M., Chiappelli, M., Olivieri, F., Cavallone, L., Giovanietti, S., Masliah, E., Franceschi, C., 2002. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the citokine in the blood and brain. Neurbiol. Aging (submitted).
67. Lieb K., Fiebich B.L., Schaller H., Berger M., Bauer J. Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha-1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B. J. Neurochem. 67:1996;2039-2044.
68. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated protein alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature. 372:1994;92-94.
69. Mancardi G.L., Liwnicz B.H., Mandybur T.I. Fibrous astrocytes in Alzheimer's disease and senile dementia of Alzheimer's type. Acta Neuropathol. (Berl). 61:1983;76-80.
70. McCusker S.M., Curran M.D., Dynan K.B., McCullagh C.D., Urquhart D.D., Middleton D., Patterson C.C., McIlroy S.P., Passmore A.P. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet. 357:2001;436-439.
71. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:1989;516-527.
72. McGeer P.L., Kawamata T., Walker D.G., Akiyama H., Tooyama I., McGeer E.G. Microglia in degenerative neurological disease. Glia. 7:1993;84-92.
73. McGeer P.L., Rogers J., McGeer E.G. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis. Assoc. Disord. 8:1994;149-158.
74. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
75. McGeer E.G., McGeer P.L. The importance of inflammatory mechanisms in Alzheimer's disease. Exp. Gerontol. 33:1998;371-378.
76. McIlroy S.P., Dynan K.B., Vahidassr D.J., Lawson J.T., Patterson C.C., Passmore P. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. Am. J. Med. Genet. 105:2001;502-506.
77. McMillian M., Kong L.Y., Sawin S.M., Wilson B., Das K., Hudson P., Hong J.S., Bing G. Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem. Biophys. Res. Commun. 215:1995;572-577.
78. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
79. Morgan K., Licastro F., Tilley L., Ritchie A., Pedrini S., Kalsheker N. Polymorphism in the alpha-1-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. Hum. Genet. 109:2001;303-310.
80. Mucke L., Masliah E., Johnson W.B., Ruppe M.D., Alford M., Rockenstein E.M., Forss-Petter S., Pietropaolo M., Mallory M., Abraham C.R. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res. 666:1994;151-167.
81. Mucke L., Yu G.Q., McConlogue L., Rockenstein E.M., Abraham C.R., Masliah E. Astroglial expression of human alpha-1-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol. 157:2000;2003-2010.
82. Murphy G.M., Sullivan E.V., Gallagher-Thompson D., Thompson L.W., van Duijn C.M., Forno L.S., Ellis W.G., Jagust W.J., Yesavage J., Tinklenberg J.R. No association between the alpha-1-antichymotrypsin A allele and Alzheimer's disease. Neurology. 19:1997;1313-1316.
83. Myllykangas L., Polvikoski T., Sulkava R., Verkkoniemi A., Crook R., Tienari P.J., Pusa A.K., Niinisto L., O'Brien P., Kontula K., Hardy J., Haltia M., Perez-Tur J. Genetic association of alpha2-macroglobulin with Alzheimer's disease in a Finnish elderly population. Ann. Neurol. 46:1999;382-390.
84. Nacmias B., Tedde A., Cellini E., Forleo P., Orlacchio A., Guarnieri B.M., Petruzzi C., D'Andrea F., Serio A., Sorbi S. Alpha2-macroglobulin polymorphisms in Italian sporadic and familial Alzheimer's disease. Neurosci. Lett. 299:2001;9-12.
85. Nicoll J.A.R., Mrak R.E., Graham D.I., Stewart J., Wilcock G., MacGowan S., Esiri M.M., Murray L.S., Dewar D., Love S., Moss T., Griffin W.S. Association of interleukin-1 gene polymorphism with Alzheimer's disease. Ann. Neurol. 47:2000;365-368.
86. Nilsson L.N., Bales K.R., DiCarlo G., Gordon M.N., Morgan D., Paul S.M., Potter H. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:2001;1444-1451.
87. Papassotiropoulos A., Bagli M., Jessen F., Rao M.L., Maier W., Heun R. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk of sporadic Alzheimer's disease. Ann. Neurol. 45:1999;666-668.
88. Pirtilla T., Mehta P.D., Frey H., Wisniewski H.M. Alpha-1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging. 15:1994;313-317.
89. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
90. Rebeck G.W. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci. Lett. 293:2000;75-77.
91. Rogaeva E.A., Premkumar S., Grubber J., Serneels L., Scott W.K., Kawarai T., Song Y., Hill D.L., Abou-Donia S.M., Martin E.R., Vance J.J., Yu G., Orlacchio A., Pei Y., Nishimura M., Supala A., Roberge B., Saunders A.M., Roses A.D., Schmechel D., Crane-Gatherum A., Sorbi S., Bruni A., Small G.W., Pericak-Vance M.A. An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat. Genet. 22:1999;19-22.
92. Rogers J., Luber-Narod J., Styren S.D., Civin W.H., Rogers J., Luber-Narod J., Styren S.D., Civin W.H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol. Aging. 9:1988;339-349.
93. Rosenberg R.N. The molecular and genetic basis of AD: the end of the beginning. Neurology. 54:2000;2045-2054.
94. Rozemuller J.M., Eikelenboom P., Pals S.T., Stam F.C. Microglial cells around amyloid plaques in Alzheimer's disease express leukocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101:1989;288-292.
95. Sawada M., Kondo N., Suzumura A., Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 491:1989;394-397.
96. Selkoe D.J. Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell. 58:1989;611.
97. Sheng J.C., Griffin W.S., Royston M.C., Mrak R.E. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implication for neuritic plaque formation in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 24:1998;278-283.
98. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid beta attenuates Alzheimer-disease-like pathology in PDAPP mouse. Nature. 400:1999;173-177.
99. Singh V.K., Guthikonda P. Circulating cytochines in Alzheimer's disease. J. Psychiatr. Res. 31:1997;657-660.
100. Singleton A.B., Gibson A.M., McKeith I.G., Ballard C.A., Perry R.H., Ince P.G., Edwardson J.A., Morris C.M. Alpha-2-macroglobulin polymorphisms in Alzheimer's disease and dementia with Lewy bodies. Neuroreport. 10:1999;1507-1510.
101. Slack B.E., Ma L.K., Seah C.C. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumor necrosis factor-alpha converting enzyme. Biochem. J. 357:2001;787-794.
102. Strauss S., Bauer J., Ganter U., Jonas U., Berger M., Volk B. Detection of interleukin-6 and α-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:1992;223-230.
103. Strohmeyer R., Shen Y., Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res. Mol. Brain Res. 81:2001;7-18.
104. Terry R.D. Neuropathological changes in Alzheimer disease. Prog. Brain Res. 101:1994;383-390.
105. Teunissen C.E., De Vente J., Steinbusch H.W.M., DeBruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging. 23:2002;485-508.
106. Tooyama I., Kimura H., Akiyama H., McGeer P.L. Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. Brain Res. 523:1990;273-280.
107. Travis J., Salvelsen G.S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52:1983;655-709.
108. Van Duijn C.M., Hofman A., Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci. Lett. 108:1990;350-354.
109. Verpillat P., Bouley S., Hannequin D., Belliard S., Puel M., Thomas-Anterion C., Dubois B., Agid Y., Campion D., Clerget-Darpoux F., Brice A. Alpha2-macroglobulin gene and Alzheimer's disease: confirmation of association by haplotypes analyses. Ann. Neurol. 48:2000;400-402.
110. Wang X., Luedecking E.K., Minster R.L., Ganguli M., DeKosky S.T., Kamboh M.I. Lack of association between alpha2-macroglobulin polymorphisms and Alzheimer's disease. Hum. Genet. 108:2001;105-108.
111. Wavrant-DeVrieze F., Rudrasingham V., Lambert J.C., Chakraverty S., Kehoe P., Crook R., Amouyel P., Wu W., Holmans P., Rice F., Perez-Tur J., Frigard B., Morris J.C., Carty S., Cottel D., Tunstall N., Lovestone S., Petersen R.C., Chartier-Harlin M.C., Goate A., Owen M.J., Williams J., Hardy J. No association between the alpha-2-macroglobulin I1000V polymorphism and Alzheimer's disease. Neurosci. Lett. 262:1999;137-139.
112. Yamada M., Sodeyama N., Itoh Y., Suematsu N., Otomo E., Matsushita M., Mizusawa H. A deletion polymorphism of alpha-(2)-macroglobulin gene and cerebral amyloid angiopathy. Stroke. 30:1999;2277-2279.